Charles Schwab’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-340,909
| Closed | -$3.06M | – | 3119 |
|
|
2016
Q3 | $3.06M | Buy |
340,909
+77,635
| +29% | +$552K | ﹤0.01% | 1920 |
|
|
2016
Q2 | $1.41M | Sell |
263,274
-35,824
| -12% | -$184K | ﹤0.01% | 2226 |
|
|
2016
Q1 | $1.38M | Buy |
299,098
+6,478
| +2% | +$26K | ﹤0.01% | 2217 |
|
|
2015
Q4 | $1.52M | Buy |
292,620
+9,354
| +3% | +$54.3K | ﹤0.01% | 2206 |
|
|
2015
Q3 | $1.71M | Buy |
283,266
+16,021
| +6% | +$196K | ﹤0.01% | 2154 |
|
|
2015
Q2 | $4.22M | Buy |
267,245
+45,965
| +21% | +$558K | 0.01% | 1647 |
|
|
2015
Q1 | $2.41M | Buy |
221,280
+9,984
| +5% | +$102K | ﹤0.01% | 1960 |
|
|
2014
Q4 | $2.22M | Buy |
211,296
+28,352
| +15% | +$277K | ﹤0.01% | 1947 |
|
|
2014
Q3 | $1.75M | Buy |
182,944
+3,584
| +2% | +$36.6K | ﹤0.01% | 2040 |
|
|
2014
Q2 | $2.07M | Buy |
179,360
+9,798
| +6% | +$89.2K | ﹤0.01% | 1966 |
|
|
2014
Q1 | $1.7M | Buy |
169,562
+32,608
| +24% | +$471K | ﹤0.01% | 2039 |
|
|
2013
Q4 | $1.78M | Buy |
136,954
+10,152
| +8% | +$140K | ﹤0.01% | 1992 |
|
|
2013
Q3 | $1.9M | Buy |
126,802
+12,408
| +11% | +$149K | ﹤0.01% | 1872 |
|
|
2013
Q2 | $1.08M | Buy |
+114,394
| New | +$775K | ﹤0.01% | 2120 |
|
Charles Schwab's RPTP Position: Q4 2016 in Review
Charles Schwab sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q4 2016, closing a stake of 340,909 shares — an estimated $3.06M sold.
Charles Schwab first reported a position in RPTP in Q2 2013 and held it in 14 quarters. The position peaked at $4.22M in Q2 2015. 0 funds tracked by Wall St. Rank hold RPTP as of Q4 2016.
- Charles Schwab reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q4 2016 after selling out during the quarter.
- Charles Schwab sold 340,909 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q4 2016, an estimated $3.06M.
- Charles Schwab first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q2 2013 and held it in 14 quarters.
- Charles Schwab's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $4.22M in Q2 2015.
- 0 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q4 2016.
Based on Charles Schwab's 13F filing for Q4 2016, filed 13 Feb 2017.